Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Study reveals what happens to blood cell production during the ageing process, which could help identify new therapeutic targets.

Inside blood vessel red and white blood cells 3D rendering

A study published in Nature Communications by the Nerlov Group sheds light on what happens to blood cell production during the ageing process. As people age, they have a declining immune response and frequently suffer from anaemia. Identifying new therapeutic targets may eventually make it possible to revert this process, boosting the immune response and avoiding anaemia.

As organisms age, the effectiveness of replenishing blood cells decreases, particular for red blood cells and those white blood cells (lymphocytes) that produce antibodies and kill virus-infected cells. This leads to higher rates of anaemia (because of fewer red blood cells), as well as too few infection-fighting white blood cells in older people. Bone marrow stem cells which give rise to all blood cell types are affected by many factors, including cues coming from the ‘microenvironment’ around the cell.

The Nerlov group set out to detect changes during ageing in the stromal cells that make up the bone marrow microenvironment. They found that both the IL-6 and TGFb signalling pathways were upregulated across multiple stromal cell types.

In particular, the researchers found that in aged mice inhibition of TGFb signalling increased the ability of aged bone marrow stem cells to generate lymphocytes. However, the age-associated decrease in red blood cell production was not due to stem cell ageing, but instead to the effect of IL-6 and TGFb signalling on the precursor cells that generate the red blood cells: by inhibiting both IL-6 and TGFb signalling both the number and function of red blood cell precursors was restored.

The computational method that the researchers used (which capitalised the MRC WIMM’s state-of-the-art genomics platforms) to uncover these processes is also novel, and can potentially be used to study both developmental and pathological processes.

Dr Simona Valletta, first author of the study said: “This important result highlights a crucial role played by the aged microenvironment within organisms in the inhibition of the generation of red blood cells, with IL-6 identified as a potential target for therapeutic intervention. Our research, understanding the underlying causes of the age-associated decrease in red and white blood cell production, and identifying pharmacological strategies to counteract them, provides significant insights for the development of new targeted treatments. This represents an important step towards improving the health of the ageing population.” 

Similar stories

Study finds new human blood disorder

MRC MHU RDM

The Patel Group have discovered a new human disease caused by formaldehyde accumulation in cells

Researchers target previously unknown ‘genetic vulnerability’ in breast cancer cells

MRC MHU NDM RDM

New Nature paper reveals discovery of a genetic vulnerability in nearly 10% of breast cancer tumours and how this can be targeted to selectively kill cancer cells.

Developing a rapid and cost-effective way to identify newborns at risk of leukaemia

MRC MHU

MRC WIMM researchers have developed a new method to quickly identify cancerous cells in babies at risk of leukaemia. The team hope that the new protocol could make rapid testing more accessible for clinical laboratories around the globe.

Nerlov and Vyas labs develop first pre-clinical model of rare leukaemia

MRC MHU

The collaboration has led to the first pre-clinical model of acute erythroid leukaemia.